Yuki Takahashi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6593274/publications.pdf

Version: 2024-02-01

116 papers	5,371 citations	126708 33 h-index	91712 69 g-index
126 all docs	126 docs citations	126 times ranked	6576 citing authors

#	Article	IF	Citations
1	Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. Journal of Biotechnology, 2013, 165, 77-84.	1.9	568
2	Macrophageâ€dependent clearance of systemically administered B16BL6â€derived exosomes from the blood circulation in mice. Journal of Extracellular Vesicles, 2015, 4, 26238.	5.5	410
3	Exosome-based tumor antigensâ€“adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials, 2016, 111, 55-65.	5.7	256
4	Quantitative Analysis of Tissue Distribution of the B16BL6-Derived Exosomes Using a Streptavidin-Lactadherin Fusion Protein and Iodine-125-Labeled Biotin Derivative After Intravenous Injection in Mice. Journal of Pharmaceutical Sciences, 2015, 104, 705-713.	1.6	217
5	Possibility of Exosome-Based Therapeutics and Challenges in Production of Exosomes Eligible for Therapeutic Application. Biological and Pharmaceutical Bulletin, 2018, 41, 835-842.	0.6	206
6	Cell type-specific and common characteristics of exosomes derived from mouse cell lines: Yield, physicochemical properties, and pharmacokinetics. European Journal of Pharmaceutical Sciences, 2017, 96, 316-322.	1.9	196
7	Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice. Biomaterials, 2011, 32, 488-494.	5.7	186
8	DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy. Biomaterials, 2017, 146, 136-145.	5.7	174
9	Design and Development of Nanosized DNA Assemblies in Polypod-like Structures as Efficient Vehicles for Immunostimulatory CpG Motifs to Immune Cells. ACS Nano, 2012, 6, 5931-5940.	7.3	157
10	Pharmacokinetics of Exosomesâ€”An Important Factor for Elucidating the Biological Roles of Exosomes and for the Development of Exosome-Based Therapeutics. Journal of Pharmaceutical Sciences, 2017, 106, 2265-2269.	1.6	157
11	Effect of exosome isolation methods on physicochemical properties of exosomes and clearance of exosomes from the blood circulation. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 98, 1-8.	2.0	147
12	Role of Phosphatidylserine-Derived Negative Surface Charges in the Recognition and Uptake of Intravenously Injected B16BL6-Derived Exosomes by Macrophages. Journal of Pharmaceutical Sciences, 2017, 106, 168-175.	1.6	145
13	Preservation of exosomes at room temperature using lyophilization. International Journal of Pharmaceutics, 2018, 553, 1-7.	2.6	144
14	Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery. Journal of Controlled Release, 2014, 180, 25-32.	4.8	124
15	Nonviral vector-mediated RNA interference: Its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Advanced Drug Delivery Reviews, 2009, 61, 760-766.	6.6	97
16	Accelerated growth of B16<scp>BL</scp>6 tumor in mice through efficient uptake of their own exosomes by B16<scp>BL</scp>6 cells. Cancer Science, 2017, 108, 1803-1810.	1.7	96
17	Blood concentrations of small extracellular vesicles are determined by a balance between abundant secretion and rapid clearance. Journal of Extracellular Vesicles, 2020, 9, 1696517.	5.5	92
18	Adiponectin Stimulates Exosome Release to Enhance Mesenchymal Stem-Cell-Driven Therapy of Heart Failure in Mice. Molecular Therapy, 2020, 28, 2203-2219.	3.7	86

#	Article	IF	Citations
19	Role of Extracellular Vesicle Surface Proteins in the Pharmacokinetics of Extracellular Vesicles. Molecular Pharmaceutics, 2018, 15, 1073-1080.	2.3	80
20	Induction of Potent Antitumor Immunity by Sustained Release of Cationic Antigen from a DNAâ€Based Hydrogel with Adjuvant Activity. Advanced Functional Materials, 2015, 25, 5758-5767.	7.8	79
21	Sustained Exogenous Expression of Therapeutic Levels of IFN-Î³ Ameliorates Atopic Dermatitis in NC/Nga Mice via Th1 Polarization. Journal of Immunology, 2010, 184, 2729-2735.	0.4	64
22	Self-Assembling DNA Dendrimer for Effective Delivery of Immunostimulatory CpG DNA to Immune Cells. Biomacromolecules, 2015, 16, 1095-1101.	2.6	62
23	Enhanced Class I Tumor Antigen Presentation via Cytosolic Delivery of Exosomal Cargos by Tumor-Cell-Derived Exosomes Displaying a pH-Sensitive Fusogenic Peptide. Molecular Pharmaceutics, 2017, 14, 4079-4086.	2.3	61
24	Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clinical and Experimental Metastasis, 2004, 21, 213-221.	1.7	59
25	Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. Journal of Gene Medicine, 2009, 11, 435-443.	1.4	59
26	Near-Infrared Fluorescence Probes for Enzymes Based on Binding Affinity Modulation of Squarylium Dye Scaffold. Analytical Chemistry, 2012, 84, 4404-4410.	3.2	55
27	Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: Quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. Journal of Controlled Release, 2005, 105, 332-343.	4.8	45
28	Self-assembling DNA hydrogel-based delivery of immunoinhibitory nucleic acids to immune cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 123-130.	1.7	42
29	Improved sustained release of antigen from immunostimulatory DNA hydrogel by electrostatic interaction with chitosan. International Journal of Pharmaceutics, 2017, 516, 392-400.	2.6	41
30	The Aldo-Keto Reductase Akr1b7 Gene Is a Common Transcriptional Target of Xenobiotic Receptors Pregnane X Receptor and Constitutive Androstane Receptor. Molecular Pharmacology, 2009, 76, 604-611.	1.0	40
31	Depressive symptoms as a side effect of Interferon-Î± therapy induced by induction of indoleamine 2,3-dioxygenase 1. Scientific Reports, 2016, 6, 29920.	1.6	40
32	Reactivation of Silenced Transgene Expression in Mouse Liver by Rapid, Large-Volume Injection of Isotonic Solution. Human Gene Therapy, 2008, 19, 1009-1020.	1.4	36
33	Transplantation of insulin-secreting multicellular spheroids for the treatment of type 1 diabetes in mice. Journal of Controlled Release, 2014, 173, 119-124.	4.8	34
34	Optimization of Albumin Secretion and Metabolic Activity of Cytochrome P450 1A1 of Human Hepatoblastoma HepG2 Cells in Multicellular Spheroids by Controlling Spheroid Size. Biological and Pharmaceutical Bulletin, 2017, 40, 334-338.	0.6	34
35	Induction of Tumor-specific Immune Response by Gene Transfer of Hsp70-cell-penetrating Peptide Fusion Protein to Tumors in Mice. Molecular Therapy, 2010, 18, 421-428.	3.7	33
36	DNA nanotechnology-based development of delivery systems for bioactive compounds. European Journal of Pharmaceutical Sciences, 2014, 58, 26-33.	1.9	33

#	Article	IF	Citations
37	Efficient delivery of immunostimulatory DNA to mouse and human immune cells through the construction of polypod-like structured DNA. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 765-774.	1.7	32
38	Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA. International Journal of Cancer, 2007, 121, 401-406.	2.3	30
39	Gene silencing of Î²â€catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. International Journal of Cancer, 2008, 123, 2315-2320.	2.3	29
40	Poly(N-isopropylacrylamide)-coated microwell arrays for construction and recovery of multicellular spheroids. Journal of Bioscience and Bioengineering, 2013, 115, 695-699.	1.1	28
41	Development of DNA-anchored assembly of small extracellular vesicle for efficient antigen delivery to antigen presenting cells. Biomaterials, 2019, 225, 119518.	5.7	28
42	Retardation of Antigen Release from DNA Hydrogel Using Cholesterolâ€Modified DNA for Increased Antigenâ€Specific Immune Response. Advanced Healthcare Materials, 2017, 6, 1700355.	3.9	27
43	Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA targeting Î²-catenin or hypoxia-inducible factor 1Î±. Journal of Controlled Release, 2006, 116, 90-95.	4.8	26
44	Efficient amplification of self-gelling polypod-like structured DNA by rolling circle amplification and enzymatic digestion. Scientific Reports, 2015, 5, 14979.	1.6	25
45	In Vivo Tracking of Extracellular Vesicles in Mice Using Fusion Protein Comprising Lactadherin and Gaussia Luciferase. Methods in Molecular Biology, 2017, 1660, 245-254.	0.4	25
46	Combined encapsulation of a tumor antigen and immune cells using a self-assembling immunostimulatory DNA hydrogel to enhance antigen-specific tumor immunity. Journal of Controlled Release, 2018, 288, 189-198.	4.8	25
47	Role of d-Elements in a Protonâ€“Electron Coupling of dâ€“Î€ Hybridized Electron Systems. Journal of the American Chemical Society, 2019, 141, 11686-11693.	6.6	25
48	Design of PCRâ€amplified DNA fragments for in vivo gene delivery: Sizeâ€dependency on stability and transgene expression. Journal of Pharmaceutical Sciences, 2007, 96, 2251-2261.	1.6	24
49	Quantitative and Temporal Analysis of Gene Silencing in Tumor Cells Induced by Small Interfering RNA or Short Hairpin RNA Expressed from Plasmid Vectors. Journal of Pharmaceutical Sciences, 2009, 98, 74-80.	1.6	24
50	Development of RNA/DNA Hydrogel Targeting Toll-Like Receptor 7/8 for Sustained RNA Release and Potent Immune Activation. Molecules, 2020, 25, 728.	1.7	24
51	Phosphatidylserine-deficient small extracellular vesicle is a major somatic cell-derived sEV subpopulation in blood. IScience, 2021, 24, 102839.	1.9	24
52	Prolonged Circulation Half-life of Interferon Î³ Activity by Gene Delivery of Interferon Î³â€“Serum Albumin Fusion Protein in Mice. Journal of Pharmaceutical Sciences, 2011, 100, 2350-2357.	1.6	23
53	Antitumor immunity by small extracellular vesicles collected from activated dendritic cells through effective induction of cellular and humoral immune responses. Biomaterials, 2020, 252, 120112.	5.7	23
54	Reconstruction of Toll-like receptor 9-mediated responses in HEK-Blue hTLR9 cells by transfection of human macrophage scavenger receptor 1 gene. Scientific Reports, 2017, 7, 13661.	1.6	21

#	Article	IF	Citations
55	Increased Insulin Secretion from Insulin-Secreting Cells by Construction of Mixed Multicellular Spheroids. Pharmaceutical Research, 2016, 33, 247-256.	1.7	20
56	Effects of Localization of Antigen Proteins in Antigen-Loaded Exosomes on Efficiency of Antigen Presentation. Molecular Pharmaceutics, 2019, 16, 2309-2314.	2.3	20
57	Enhancement of antiproliferative activity of interferons by RNA interferenceâ€mediated silencing of SOCS gene expression in tumor cells. Cancer Science, 2008, 99, 1650-1655.	1.7	19
58	Development of allergic rhinitis immunotherapy using antigen-loaded small extracellular vesicles. Journal of Controlled Release, 2022, 345, 433-442.	4.8	18
59	Optimal Arrangement of Four Short DNA Strands for Delivery of Immunostimulatory Nucleic Acids to Immune Cells. Nucleic Acid Therapeutics, 2015, 25, 245-253.	2.0	17
60	Control of polarization and tumoricidal activity of macrophages by multicellular spheroid formation. Journal of Controlled Release, 2018, 270, 177-183.	4.8	17
61	Development of orally-deliverable DNA hydrogel by microemulsification and chitosan coating. International Journal of Pharmaceutics, 2018, 547, 556-562.	2.6	17
62	Therapeutic Application of Small Extracellular Vesicles (sEVs): Pharmaceutical and Pharmacokinetic Challenges. Biological and Pharmaceutical Bulletin, 2020, 43, 576-583.	0.6	17
63	Increased immunostimulatory activity of polypod-like structured DNA by ligation of the terminal loop structures. Journal of Controlled Release, 2012, 163, 285-292.	4.8	16
64	Amelioration of Experimental Autoimmune Encephalomyelitis in Mice by Interferon-Beta Gene Therapy, Using a Long-Term Expression Plasmid Vector. Molecular Pharmaceutics, 2017, 14, 1212-1217.	2.3	16
65	Interleukin-4-carrying small extracellular vesicles with a high potential as anti-inflammatory therapeutics based on modulation of macrophage function. Biomaterials, 2021, 278, 121160.	5.7	16
66	Constant and steady transgene expression of interferonâ€Î³ by optimization of plasmid construct for safe and effective interferonâ€Î³ gene therapy. Journal of Gene Medicine, 2012, 14, 288-295.	1.4	15
67	Prevention of adverse events of interferon Î³ gene therapy by gene delivery of interferon Î³-heparin-binding domain fusion protein in mice. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14023.	1.8	15
68	Using sizeâ€controlled multicellular spheroids of murine adenocarcinoma cells to efficiently establish pulmonary tumors in mice. Biotechnology Journal, 2017, 12, 1600513.	1.8	15
69	DNA density-dependent uptake of DNA origami-based two-or three-dimensional nanostructures by immune cells. Nanoscale, 2020, 12, 14818-14824.	2.8	15
70	InÂVitro and InÂVivo Stimulation of Toll-Like Receptor 9 by CpG Oligodeoxynucleotides Incorporated Into Polypod-Like DNA Nanostructures. Journal of Pharmaceutical Sciences, 2017, 106, 2457-2462.	1.6	14
71	Controlling the kinetics of interferon transgene expression for improved gene therapy. Journal of Drug Targeting, 2012, 20, 764-769.	2.1	13
72	Nasal delivery of Japanese cedar pollen Cryj1 by using self-gelling immunostimulatory DNA for effective induction of immune responses in mice. Journal of Controlled Release, 2015, 200, 52-59.	4.8	13

#	Article	IF	Citations
73	Safe and effective interferon-beta gene therapy for the treatment of multiple sclerosis by regulating biological activity through the design of interferon-beta-galectin-9 fusion proteins. International Journal of Pharmaceutics, 2018, 536, 310-317.	2.6	13
74	Expression Profile-Dependent Improvement of Insulin Sensitivity by Gene Delivery of Interleukin-6 in a Mouse Model of Type II Diabetes. Molecular Pharmaceutics, 2013, 10, 3812-3821.	2.3	12
75	Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus. Antiviral Research, 2017, 146, 130-138.	1.9	12
76	Determining The Role of Surface Glycans in The Pharmacokinetics of Small Extracellular Vesicles. Journal of Pharmaceutical Sciences, 2021, 110, 3261-3267.	1.6	11
77	Moment analysis for kinetics of gene silencing by RNA interference. Biotechnology and Bioengineering, 2006, 93, 816-819.	1.7	10
78	Positive Correlation Between the Generation of Reactive Oxygen Species and Activation/Reactivation of Transgene Expression After Hydrodynamic Injections into Mice. Pharmaceutical Research, 2011, 28, 702-711.	1.7	9
79	Saturation of transgene protein synthesis from mRNA in cells producing a large number of transgene mRNA. Biotechnology and Bioengineering, 2011, 108, 2380-2389.	1.7	9
80	Enhancement of Anticancer Effect of Interferon-Î³ Gene Transfer against Interferon-Î³-Resistant Tumor by Depletion of Tumor-Associated Macrophages. Molecular Pharmaceutics, 2014, 11, 1542-1549.	2.3	9
81	SELEX-Based Screening of Exosome-Tropic RNA. Biological and Pharmaceutical Bulletin, 2017, 40, 2140-2145.	0.6	9
82	Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response. Nanomedicine, 2020, 15, 1641-1652.	1.7	9
83	Enhanced Immunostimulatory Activity of Covalent DNA Dendrons. ChemBioChem, 2022, 23, .	1.3	9
84	Persistent interferon transgene expression by RNA interferenceâ€mediated silencing of interferon receptors. Journal of Gene Medicine, 2010, 12, 739-746.	1.4	8
85	Removal of transgene-expressing cells by a specific immune response induced by sustained transgene expression. Journal of Gene Medicine, 2014, 16, 97-106.	1.4	7
86	Contribution of Epigenetic Modifications to the Decline in Transgene Expression from Plasmid DNA in Mouse Liver. Pharmaceutics, 2015, 7, 199-212.	2.0	7
87	Interferon-Inducible Mx Promoter-Driven, Long-Term Transgene Expression System of Interferon-Î² for Cancer Gene Therapy. Human Gene Therapy, 2016, 27, 936-945.	1.4	7
88	Elucidation of the Mechanism of Increased Activity of Immunostimulatory DNA by the Formation of Polypod-like Structure. Pharmaceutical Research, 2017, 34, 2362-2370.	1.7	7
89	Critical contribution of macrophage scavenger receptor 1 to the uptake of nanostructured DNA by immune cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 34, 102386.	1.7	7
90	Development of Hydrophobic Interaction-based DNA Supramolecules as Efficient Delivery Carriers of CpG DNA to Immune cells. Journal of Pharmaceutical Sciences, 2022, 111, 1133-1141.	1.6	7

#	Article	IF	Citations
91	Inhibition of surgical trauma-enhanced peritoneal dissemination of tumor cells by human catalase derivatives in mice. Free Radical Biology and Medicine, 2011, 51, 773-779.	1.3	6
92	Gene delivery of albumin binding peptide-interferon-gamma fusion protein with improved pharmacokinetic properties and sustained biological activity. Journal of Pharmaceutical Sciences, 2013, 102, 3110-3118.	1.6	6
93	Application of Magnesium Pyrophosphateâ€“Based Sponge-Like Microparticles to Enhance the Delivery Efficiency and Adjuvant Effects of Polyriboinosinic-Polyribocytidylic Acid in Immune Cells. Journal of Pharmaceutical Sciences, 2016, 105, 766-772.	1.6	6
94	Intercellular delivery of NF-ÎºB inhibitor peptide utilizing small extracellular vesicles for the application of anti-inflammatory therapy. Journal of Controlled Release, 2020, 328, 435-443.	4.8	6
95	Long-Term Elimination of Hepatitis C Virus from Human Hepatocyte Chimeric Mice After Interferon-Î³ Gene Transfer. Human Gene Therapy Clinical Development, 2014, 25, 28-39.	3.2	5
96	Atomic force microscopy analysis of orientation and bending of oligodeoxynucleotides in polypod-like structured DNA. Nano Research, 2015, 8, 3764-3771.	5.8	5
97	Development of a Nanostructured RNA/DNA Assembly as an Adjuvant Targeting Toll-Like Receptor 7/8. Nucleic Acid Therapeutics, 2019, 29, 335-342.	2.0	5
98	Combined use of chemically modified nucleobases and nanostructured DNA for enhanced immunostimulatory activity of CpG oligodeoxynucleotide. Bioorganic and Medicinal Chemistry, 2021, 29, 115864.	1.4	5
99	Enhanced Activity of Immunosuppressive Oligodeoxynucleotides by Incorporating Them into Hexapod-Like Nanostructured DNA. Biological and Pharmaceutical Bulletin, 2018, 41, 564-569.	0.6	4
100	pH Responsiveness of Near-infrared Fluorescent Cyanine Dyes Encapsulated in Self-assemblies Composed of Various Amphiphiles. Chemistry Letters, 2018, 47, 1147-1150.	0.7	4
101	Regulation of the Distribution of Cells in Mixed Spheroids by Altering Migration Direction. Tissue Engineering - Part A, 2019, 25, 390-398.	1.6	4
102	Calcium Peroxide-Containing Polydimethylsiloxane-Based Microwells for Inhibiting Cell Death in Spheroids through Improved Oxygen Supply. Biological and Pharmaceutical Bulletin, 2021, 44, 1458-1464.	0.6	4
103	Fibronectin inhibits cytokine production induced by CpG DNA in macrophages without direct binding to DNA. Cytokine, 2012, 60, 162-170.	1.4	3
104	Construction of nanostructured DNA harbouring phosphorodiamidate morpholino oligonucleotide for controlled tissue distribution in mice. Journal of Drug Targeting, 2018, 26, 373-381.	2.1	3
105	Folding of single-stranded circular DNA into rigid rectangular DNA accelerates its cellular uptake. Nanoscale, 2019, 11, 23416-23422.	2.8	3
106	Incorporation of Gelatin Microspheres into HepG2 Human Hepatocyte Spheroids for Functional Improvement through Improved Oxygen Supply to Spheroid Core. Biological and Pharmaceutical Bulletin, 2020, 43, 1220-1225.	0.6	3
107	Development of multicellular spheroid for cell-based therapy. Drug Delivery System, 2013, 28, 45-53.	0.0	2
108	Comparison of antigen expression from plasmid DNA in tumor-free and antigen-expressing tumor-bearing mice. Human Vaccines and Immunotherapeutics, 2012, 8, 194-200.	1.4	1

#	Article	IF	Citations
109	Targeted Delivery of Interferon Gamma Using a Recombinant Fusion Protein of a Fibrin Clotâ€“Binding Peptide With Interferon Gamma for Cancer Gene Therapy. Journal of Pharmaceutical Sciences, 2017, 106, 892-897.	1.6	1
110	Analysis of Tertiary Structural Features of Branched DNA Nanostructures with Partially Common Sequences Using Small-Angle X-ray Scattering. ACS Applied Bio Materials, 2020, 3, 308-314.	2.3	1
111	Characteristics of Exosomes and Development of Exosome-based Diagnosis and Therapy. Oleoscience, 2014, 14, 291-298.	0.0	0
112	In vivo fate of exogenously-administered exosomes. Drug Delivery System, 2014, 29, 116-124.	0.0	0
113	Development of exosome-based DDS targeting gastrointestinal cancer. Drug Delivery System, 2018, 33, 372-376.	0.0	0
114	Exosomes in Cancer Immunotherapy. , 2018, , 313-324.		0
115	Development of immunotherapy using extracellular vesicles. Drug Delivery System, 2021, 36, 100-107.	0.0	0
116	Delivery of vectors expressing short hairpin RNA for cancer therapy. Drug Delivery System, 2007, 22, 123-130.	0.0	0